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OBJECTIVES We evaluated whether the relationship between hypertension, other cardiac risk factors, and
coronary artery disease (CAD) is modulated by menopausal status and/or age.
BACKGROUND The relative contribution of age versus menopausal status in the development of CAD in
women remains unclear.
METHODS We compared systolic blood pressure (SBP), diastolic blood pressure (DBP), pulse pressure
(PP), and traditional cardiac risk factors for CAD in premenopausal (n  123) and
postmenopausal (n  482) women undergoing coronary angiography for suspected ischemia.
To assess the relative contribution of age versus menopausal status, we fit a hypertension-
menopausal status interaction term and adjusted for age.
RESULTS There were similar relationships with regard to traditional coronary risk factors and
angiographic CAD in premenopausal versus postmenopausal women, with few exceptions.
Twenty percent of premenopausal women had angiographic CAD versus 31% of postmeno-
pausal women (p  0.02). Premenopausal women had lower mean (standard deviation) SBP
(132 [25] vs. 139 [20] mm Hg; p  0.0001) and lower PP (54 [18] vs. 62 [18] mm Hg; p
 0.0001) compared to postmenopausal women; however, multivariable analyses revealed
that SBP was a risk factor for CAD in premenopausal (p  0.002) but not postmenopausal
women (p  0.13), and regression slopes were significantly different (p  0.04). This
interaction effect remained after age adjustment, suggesting independent risk contribution
from both age and menopausal status. A similar slope difference was observed for PP (p 
0.03) but not for DBP.
CONCLUSIONS Among women undergoing angiography for suspected ischemia, elevated SBP and PP are
potent risk factors in premenopausal women. The results suggest that identification of
hypertension in premenopausal women dictates additional CAD risk factor assessment and
management. (J Am Coll Cardiol 2006;47:50S–8S) © 2006 by the American College of
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.02.099Cardiology Foundation
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the relationship between hypertension and heart disease is
ell established (1), and recent statements from the Amer-
can Heart Association and the Joint National Committee
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igh Blood Pressure (JNC) have emphasized the impor-
ance of maintaining low blood pressure for prevention of
eart disease and stroke (2,3). Specifically, renewed empha-
is is being placed on detection and management of known
isk factors for coronary artery disease (CAD) as early as age
0 years (2). Despite its high prevalence in the population,
ypertension in women has received little attention in
omparison to men (4–6). Beginning in adolescence and
hrough middle age, men tend to exhibit higher mean
ystolic blood pressure (SBP) and diastolic blood pressure
DBP) than women (7–10). However, a crossover in the
revalence of hypertension in men versus women, with older
omen having more hypertension than their age-matched
ale counterparts, has been reported in several epidemio-
ogic studies (11) but not in others (12). Whether repro-
uctive hormones account for this sexually dimorphic pat-
ern of blood pressure remains a matter of controversy (13).
Recent data suggest that women develop high blood
ressure, especially systolic hypertension, at an increased
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February 7, 2006:50S–8S Hypertension, Menopausal Status, and CAD Risk in Womenate as they age (14). Furthermore, it has been noted that
omen develop CAD at a later age than men, particularly
fter menopause (15). For this reason, it has been suggested
hat the loss of reproductive hormones associated with
ostmenopausal status is a risk factor for both hypertension
16) and CAD (17–22). It is unclear, however, to what
xtent the increase in blood pressure and consequent CAD
isk after reaching menopause represent hormonal changes
ersus simply advancing age. Recent clinical trials have
aised more questions regarding the protective role of
strogen in CAD (23–27), and this phenomenon is still
nder debate (28–31).
Prior studies have suggested a more adverse prognosis
fter myocardial infarction in women compared to men
32–35), particularly among hypertensive women (5). This
as attributed to older age and greater comorbidity burden
32), although recent data have shown that younger women
ith CAD evidence a more adverse prognosis compared to
ge-matched men (34,35). Specifically, Vaccarino et al. (34)
emonstrated that among women under 50 years of age, the
arly myocardial infarction mortality rate was more than
wice that for age-matched men (6.1% vs. 2.9%; p  0.001
or interaction between age and gender). Assessment of
AD severity indicators, as well as medical treatment
egimens did not readily explain this mortality difference
34).
Therefore, we evaluated the following research questions
mong women enrolled in the Women’s Ischemia Syn-
rome Evaluation (WISE) study: 1) Are there important
ifferences in blood pressure and other traditional cardiac
isk factors between premenopausal and postmenopausal
omen? 2) Is blood pressure differently related to CAD in
remenopausal versus postmenopausal women? And 3) If
o, what is the relative contribution of menopausal status as
pposed to age in modulating the relationship between
ypertension and angiographic CAD?
ATERIALS AND METHODS
tudy population. The study population consisted of 671
omen clinically referred for coronary angiography for
uspected myocardial ischemia and enrolled in the WISE
Abbreviations and Acronyms
CAD  coronary artery disease
CI  confidence interval
DBP  diastolic blood pressure
JNC  Joint National Committee on Prevention,
Detection, Evaluation, and Treatment of High
Blood Pressure
OR  odds ratio
PP  pulse pressure
SBP  systolic blood pressure
SD  standard deviation
WISE  Women’s Ischemia Syndrome Evaluationtudy. The WISE study is a National Heart, Lung, and tlood Institute (NHLBI)-sponsored four-center study that
ims to improve diagnostic testing and advance new hy-
otheses relative to the pathophysiology of ischemic heart
isease in women. Study exclusion criteria included preg-
ancy, cardiomyopathy, New York Heart Association func-
ional class IV congestive heart failure, recent myocardial
nfarction or revascularization, and any contraindications to
rovocative testing. Perimenopausal women (n  49) and
omen with indeterminate menopausal status (n  17)
ere not included in the present analysis. The complete
tudy design and methodology of the WISE study have
een described elsewhere (36).
For the analyses presented here, we examined 605 WISE
tudy participants without a prior diagnosis of CAD, and
ith complete reproductive status and coronary angio-
raphic data. The procedures followed were in accordance
ith each center’s institutional guidelines, the study was
pproved by an institutional review committee at each site,
nd all participants gave informed consent.
aseline evaluation. Women referred for coronary an-
iography for chest pain symptoms or suspected ischemia
nderwent an initial evaluation that included collection of
emographic variables, medical history, physical activity,
nd psychosocial and symptom data. Participants underwent
physical examination that included heart rate, height,
eight, body mass index, waist-hip ratio determination, and
lood pressure evaluation. Lipoprotein determinations
triglycerides and total and high-density lipoprotein choles-
erol) were performed at a lipid core laboratory enrolled in
he Centers for Disease Control and Prevention lipid
tandardization program with experience in NHLBI-
ponsored lipid-lowering intervention trials (37). Low-
ensity lipoprotein cholesterol was estimated using the
riedewald formula (37).
lood pressure evaluation. Blood pressure was measured
ollowing routine clinical standards as outlined by the JNC
38), using equipment that met certification criteria (39).
he study nurse at each site began measurements after at
east 5 min of rest; patients were seated, and both SBP and
BP were recorded. The first appearance of sound (phase 1)
as used to define SBP. The disappearance of sound (phase
) was used to define DBP. Two separate readings were
aken and averaged. Pulse pressure (PP) was defined as the
ifference between SBP and DBP.
etermination of menopausal status. Reproductive hor-
one assays (E2, bioavailable E2, estrone, progesterone,
ollicle-stimulating hormone, and luteinizing hormone)
ere performed at the WISE reproductive hormone core
aboratory from stored serum samples by an experienced
echnician (40). Validated steroid and protein assay meth-
ds were used, samples were assayed in batches of 100, and
ach determination was measured in duplicate. Consistent
ethodology was maintained for the duration of the study.
revious work from this laboratory has demonstrated that
ithin- and between-assay coefficients of variation, respec-ively, were 15% and 16% for estrone, 8% and 12% for E2,
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nd postmenopausal status were determined using a repro-
uctive status algorithm developed for the WISE study that
ses both reproductive historical variables and reproductive
lood hormone levels to initially assign status, followed by
xpert consensus adjudication by a committee that included
wo reproductive endocrinologists (36,42).
easurement of coronary angiography. Coronary angio-
rams were assessed by the WISE core laboratory used in
revious multicenter trials with angiographic outcomes (43).
easurements included quantitative assessment of the pres-
nce, severity, and complexity of epicardial coronary artery
tenosis, using previously published methods, and a coro-
ary severity index (43). For these analyses, angiographic
AD was defined as50% luminal diameter stenosis in1
picardial coronary artery, and multivessel CAD was de-
ned as 50% luminal diameter stenosis in 2 epicardial
oronary arteries.
tatistical analysis. Comparisons between premenopausal
nd postmenopausal women were performed by the Wil-
oxon rank sum test for continuous measures and by the
hi-square test for discrete measures. Fisher exact test for
iscrete measures was used when expected cell counts were
5. Age-adjusted p values were obtained by logistic or
inear regression, where appropriate. In general, when mul-
ivariable comparisons were significant but became nonsig-
ificant when adjusted for age, the difference was considered
ge related. When multivariable comparisons were nonsig-
ificant but became significant when adjusted for age, the
ifference was considered menopausal status related. When
nadjusted and adjusted comparisons were both significant,
he difference was considered independently related to both
ge and menopausal status. Finally, to determine the inde-
endent association between the hypertension variables and
able 1. Demographic, Coronary Risk Factor, and Medication P
Variable
Premenopausal
(All, n  123)
Postmenopausal
(All, n  482) p Valu
ge, yrs, mean (SD) 43(6) 62(9) 0.000
ace (% white) 76 84 0.05
urrent smoking (%) 27 17 0.01
istory of DM (%) 20 20 0.85
istory of
hypertension (%)
47 57 0.06
istory of dyslipidemia
(%)
35 53 0.000
amily history of
premature CAD (%)
72 66 0.16
ipid lowering (%) 13 22 0.02
spirin (%) 35 58 0.000
eta-blockers (%) 35 31 0.37
ntihypertensive
medications (%)*
27 46 0.000
nsulin/oral (%) 17 16 0.98
ormone therapy (%) 11 46 0.000
Antihypertensive medications include angiotensin-converting enzyme inhibitors, an
CAD  angiographic coronary artery disease defined as 50% luminal diameterAD, we used stepwise multivariable logistic regression pnalysis to model angiographic CAD as a function of the
ypertension variables and menopausal status. The differ-
ntial impact of menopausal status on these relationships
as examined by fitting a risk factor/menopausal status
nteraction term. Probability values of 0.05 were consid-
red statistically significant. All tests of statistical signifi-
ance were two tailed. Analyses were performed using SAS
oftware release 8.0 (SAS Institute, Cary, North Carolina).
ESULTS
aseline characteristics. Among the 605 WISE study
articipants without a prior diagnosis of CAD, and with
omplete demographic, reproductive status, and coronary
ngiographic data, the mean (SD) age was 58 (11) years,
anging from 21 to 85 years; 18% were racial minorities
primarily African American); and 80% were postmeno-
ausal. In this population, there was a high prevalence of
AD risk factors, including diabetes (20%), dyslipidemia
49%), hypertension (55%), history of smoking (50%), and
besity (mean [SD] body mass index  29.9 [7]). Despite
his prevalent coronary risk factor load, only 174 (29%) of
hese women had angiographic CAD, including 25 (20%)
remenopausal and 149 (31%) postmenopausal women.
omparisons of premenopausal versus postmenopausal
omen. Comparative demographic, coronary risk factor,
nd medication variables by premenopausal versus post-
enopausal women are shown in Tables 1 and 2. As
xpected, premenopausal women were significantly younger
ompared to the postmenopausal women: mean (SD, range)
3 (6, 21 to 54) versus 62 (9, 36 to 85); p 0.0001. Among
he overall population, there were no significant group
ifferences in coronary risk factors after adjusting for age,
ith the exception of current smoking which was more
of WISE Women by Menopausal Status
p Value,
Age-
Adjusted
Premenopausal
(With CAD,
n  25)
Postmenopausal
(With CAD,
n  149) p Value
p Value
Age-
Adjuste
— 46(5) 66(9) 0.0001 —
0.41 72 81 0.29 0.80
0.002 28 16 0.16 0.06
0.37 44 31 0.22 0.26
0.26 64 64 0.98 0.62
0.47 41 67 0.02 0.09
0.85 62 68 0.56 0.37
0.30 20 32 0.21 0.83
0.31 68 72 0.71 0.85
0.05 52 34 0.09 0.22
0.11 48 50 0.85 0.80
0.59 40 25 0.11 0.25
0.0001 17 34 0.09 0.005
sin receptor blockers, diuretics, and vasodilators.
is in 1 epicardial coronary artery; DM  diabetes mellitus.rofile
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djusted for age (p  0.002). Furthermore, there were no
ge-adjusted differences in measured blood pressure, waist-
ip ratio, fasting blood sugar, and body mass index. How-
ver, the premenopausal women had lower age-adjusted
otal cholesterol (p  0.001) and low-density lipoprotein
holesterol (p  0.02), but also lower high-density lipopro-
ein cholesterol (p 0.02) than the postmenopausal women
Table 2). Although postmenopausal women were more
ikely to use aspirin, lipid-lowering, and antihypertensive
edications, these differences disappeared when adjusting
or age, suggesting an age-related prevalence of such med-
cation use (Table 1).
The prevalence of angiographic CAD by menopausal
tatus is shown in Table 3. Despite their largely similar
ge-adjusted coronary risk factor profiles, premenopausal
omen had a lower yet substantial prevalence of angio-
raphic CAD as compared to postmenopausal women (20%
s. 31%). Similarly, the mean CAD severity index was
ignificantly higher in postmenopausal women (p 
.0001). These differences remained significant after age
djustment (p 0.01). Premenopausal and postmenopausal
omen did not differ in the actual prevalence of multivessel
ngiographic CAD (p  0.17); however, a significant
ifference emerged after adjustment for age (p  0.02).
We next evaluated the subgroup (n  174) of WISE
tudy women with angiographic CAD, defined as 50%
tenosis in 1 epicardial coronary artery. Although the
verall demographics and risk factor differences between
remenopausal and postmenopausal women remained the
ame, a major reversal was noted in the hypertension
ariables. Premenopausal women with angiographic CAD
xhibited a higher SBP (147 [35] vs. 141 [21] mm Hg) and
P (66 [27] vs. 64 [19] mm Hg) than their postmenopausal
ounterparts, a difference that became significant after age
djustment (p  0.03 and 0.02, respectively) (Table 2). The
remenopausal and postmenopausal women with angio-
raphic CAD had similar age-adjusted usages of lipid-
owering, aspirin, beta-blocker, and antihypertensive medi-
ations, and hormone therapy use, not surprisingly, was
ignificantly higher in the postmenopausal women (p 
.005).
Among this subgroup, comparison of the severity of
ultivessel angiographic CAD status by menopausal status
emonstrated that premenopausal women had a relatively
imilar prevalence of multivessel CAD (48% vs. 49% of
ostmenopausal women) and a similar mean (range) coro-
ary severity index to that of the postmenopausal women
24 [5 to 78] vs. 27 [5 to 78]). Age adjustment did not
ignificantly alter these results.
ultivariable analyses. To describe the presence of CAD,
he explanatory variables of age, race, current smoking,
lood lipoprotein levels, SBP, PP, and body mass index
ere considered with the following results: Among the
verall population, age was the most significantly associatedwith CAD (odds ratio [OR] 1.05, 95% confidence intervalTa
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ncrement in age an associated 66% elevation in the presence
f angiographic CAD resulted (95% CI 1.36 to 2.03).
Whether menopausal status modulates the relationship
etween hypertension and angiographic CAD was then
xplored. Angiographic CAD was modeled as a function of
ypertension, menopausal status, and the interaction be-
ween hypertension and menopausal status among the 605
ISE study participants; the model was then adjusted for
ge. A significant differential impact of menopausal status
as detected with respect to SBP and PP but not to DBP.
lthough SBP was lower in the premenopausal women
Table 2), regression analyses including the interaction
etween SBP and menopausal status demonstrated that
BP was paradoxically a more potent risk factor for CAD in
he premenopausal women (p  0.002) than in the post-
enopausal women (p  0.13), and the regression slopes
ere significantly different (p  0.04 for interaction) (Table
, Fig. 1A). For every 10-mm Hg increase in SBP, the odds
f CAD for premenopausal women increased 35% (95% CI
.11 to 1.64; p  0.002), whereas the odds for postmeno-
ausal women increased 7% (95% CI 0.98 to 1.18; p 
.13). This significant interaction effect remained even after
djusting for age (p  0.02). Controlling for race, antihy-
ertensive medications and hormone therapy also did not
ffect results (p  0.02; data not shown). A similar slope
ifference was observed for PP (p  0.03 for interaction)
Table 4, Fig. 1B) but not for DBP (p  0.13). For every
0-mm Hg increment in PP, the odds of CAD for
remenopausal women increased 48% (95% CI 1.16 to 1.90;
 0.001), whereas the odds of CAD for postmenopausal
omen increased 10% (95% CI 0.99 to 1.23; p  0.07).
gain, the interaction remained significant after adjustment
or age (p  0.01) (Table 4), and controlling for race,
ntihypertensive treatment, and hormone therapy use did
ot further influence results (p  0.01; data not shown).
he age-adjusted models shown in Table 4 were evaluated
or linear relationships among variables in the model (col-
inearity) which have the potential of rendering significance
esting unreliable. Using standard diagnostic techniques
44), these models were found to be fairly reliable (tolerance
0.58; condition index  14.7), suggesting mild collinear-
ty between age and menopausal status.
In order to describe the presence of CAD in premeno-
ausal and postmenopausal women separately, the explan-
tory variables of age, race, current smoking, blood lipopro-
able 3. Prevalence of Angiographic CAD for WISE Women by
Variable
All WISE Women
(n  605)
P
(
AD (%) 29
ultivessel CAD (%) 14
oronary severity index, mean (SD) 12 (13)
AD  angiographic coronary artery disease defined as 50% luminal diameter sten
oronary arteries.ein levels, SBP, PP, and body mass index were considered hn subgroup analyses. Results for postmenopausal women
ere similar to those of the overall population: age remained
he variable most significantly associated with CAD (OR
.07, 95% CI 1.04 to 1.10; p  0.0001). However, for
remenopausal women SBP emerged as the most powerful
isk factor even after adjusting for the other CAD risk
actors (OR 1.02, 95% CI 1.005 to 1.05; p  0.01).
pecifically, in the premenopausal women, cigarette smok-
ng did not have a main effect on CAD prevalence or
everity.
To interpret these results within the context of current
linical standards, the JNC VII criterion for hypertension
as applied. The JNC VII defines systolic hypertension in
dults age 18 years or over as SBP 140 mm Hg (3).
mong premenopausal WISE study women, 26% (n  32)
ad an SBP of 140 or higher at their baseline evaluation.
he odds of angiographically defined CAD were 5.6 times
igher among those premenopausal women who had an
BP 140 mm Hg, (OR 5.59, 95% CI 2.18 to 14.31) as
ompared to premenopausal women with SBP 140 mm
g, and this result was statistically significant (p 0.0003).
lthough a substantial proportion of hypertensive premeno-
ausal women reported a history of diabetes (47%), the odds
f CAD were still substantially increased for premenopausal
omen with SBP 140 mm Hg after adjustment for
istory of diabetes and antihypertensive medication use (OR
.37, 95% CI 1.19 to 9.53; p  0.02).
ISCUSSION
mong women undergoing coronary angiography for sus-
ected myocardial ischemia, premenopausal women had a
ubstantial prevalence of CAD despite their relatively lower
isk profile. Prior work in younger CAD patients has
rimarily focused on men (45), although premenopausal
omen represent about 20% of all CAD deaths among
omen annually (46). Notably, the current study results
stablished that the age-adjusted prevalence of multivessel
AD was virtually equivalent in the subgroups of premeno-
ausal and postmenopausal women with angiographic
AD.
These findings demonstrated relatively similar relation-
hips between traditional coronary risk factors and angio-
raphic CAD in premenopausal versus postmenopausal
omen, with few exceptions. Although the premenopausal
omen were more likely to be smokers, smoking did not
nopausal Status
opausal
 123)
Postmenopausal
(All, n  482) p Value
p Value,
Age-Adjusted
20 31 0.02 0.02
10 15 0.17 0.02
(11) 13 (13) 0.0001 0.01
1 epicardial coronary artery; Multivessel CAD  50% stenosis in 2 epicardialMe
remen
All, n
9ave a main effect on angiographic disease prevalence or
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mall number of premenopausal women with prevalent
AD. Although prior reports have emphasized the high
revalence of cigarette smoking and single-vessel disease in
elatively young CAD patients (45,47,48), these reports
ave focused on myocardial infarction patients and therefore
ay represent a selection bias in favor of acute thrombotic
vents as opposed to the coronary artery atherosclerotic
rocess.
There were no differences in the multivariable models of
oronary risk factors that were attributable to age versus
enopause, possibly due to mild collinearity between these
wo variables. Age-adjusted differential relationships be-
ween PP and SBP and menopausal status were found in the
ISE study population. Both interaction effects remained
ignificant even after adjustment for age, suggesting inde-
endent risk contribution from both age and menopausal
tatus. The influence of menopause on blood pressure in
omen is not well understood. Blood pressure changes
igure 1. Increasing (A) systolic blood pressure (SBP, mm Hg) and (B)
able 4. All WISE Women: Variation of the Effect of Menopau
resence of CAD, Adjusted and Unadjusted for Age
Model
Increase in Odds of
CAD (95% CI) p
BP (mm Hg)* 1.03 (1.01–1.05) 0
P status‡ 38.16 (1.87–776.52) 0
BP  MP status 0.98 (0.96–0.99) 0
ge —
ax-rescaled R2 0.04
oodman-Kruskal c 0.58
P (mm Hg)† 1.04 (1.01–1.07) 0
P status‡ 8.98 (1.67–48.04) 0
P  MP status 0.97 (0.94–1.0) 0
ge —
ax-rescaled R2 0.05
oodman-Kruskal c 0.59
Data are missing for one premenopausal and three postmenopausal women. †Data
as coded as 0 for premenopausal and 1 for postmenopausal women. Age, SBP, an
CAD  angiographic coronary artery disease defined as 50% luminal diameter s
pulse pressure; SBP  systolic blood pressure.remenopausal (PRE) and postmenopausal (POST) women. *CAD  angiogra
1 epicardial coronary artery.ssociated with menopause are difficult to evaluate, because
enopause coincides with aging. In an observational study
f 11,000 women in Italy, menopause had no predictive
ole and was rejected from the multivariable equations of
isk, with cardiovascular risk being completely explained by
ge and blood pressure (30). Prospective cohort studies have
ot found an increase in blood pressure with menopause
18, 49–53); however, results from cross-sectional studies
ave been equivocal, with some studies finding significantly
igher SBP and DBP in postmenopausal than in premeno-
ausal women (14, 54–57) and other studies finding little or
o association (58,59). In contrast, among the WISE study
omen with angiographic CAD, premenopausal women
resented with significantly higher SBP and PP than their
ostmenopausal counterparts.
Moreover, estimating the interaction effect between
lood pressure and menopausal status in the overall cohort
emonstrated that both SBP and PP were more potent risk
actors for CAD in the premenopausal group. Whereas
pressure (PP, mm Hg) and odds of coronary artery disease (CAD) in
tatus, Systolic Blood Pressure, and Pulse Pressure on the
e
Age-Adjusted Increase in
Odds of CAD (95% CI)
p Value,
Age-Adjusted
1.03 (1.01–1.04) 0.008
12.92 (0.64–260.7) 0.10
0.97 (0.95–1.0) 0.02
1.08 (1.05–1.1) 0.0001
0.14
0.69
1.03 (1.01–1.06) 0.006
3.15 (0.57–17.26) 0.19
0.97 (0.94–0.99) 0.01
1.08 (1.05–1.1) 0.0001
0.14
0.69
ssing for one premenopausal and four postmenopausal women. ‡Menopausal status
ere included as continuous variables.
s in 1 epicardial coronary artery; CI  confidence interval; MP  menopausal; PPpulsesal S
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redictor of coronary heart disease risk in younger men (60),
easures of SBP may be a strong prognostic factor of
arotid artery atherosclerosis in premenopausal women (61).
ecent data from the Healthy Women Study demonstrated
hat premenopausal SBP and PP were predictive of carotid
ntimal-medial thickness and plaque 5 to 8 years after
enopause (61), suggesting that premenopausal levels of
BP and PP may identify high-risk younger women. The
ISE study has confirmed these findings in a different
opulation of women with suspected angiographic CAD.
Despite having relatively similar age-adjusted risk factor
oads, unadjusted aspirin and antihypertensive medication
sage was lower among the premenopausal women, al-
hough this unadjusted difference was no longer evident
mong women with angiographic CAD. In addition, the
ifference in antihypertensive therapy between premeno-
ausal and postmenopausal women did not account for the
ignificant interaction effects between PP, SBP, and meno-
ausal status. Still, a minority of women in our population
ith evident CAD were treated with appropriate medica-
ions. Prior analyses have indicated that a variety of cardio-
ascular treatments are underutilized and understudied in
omen as compared with men (62–64), although contro-
ersy exists regarding the appropriateness of this treatment
attern (65). Current guidelines for the diagnosis and
reatment of hypertension are not gender specific (3), and
ew studies have examined treatment by either age or
enopausal status (13,34). However, younger women have
ypically been excluded from most antihypertensive trials
wing to potential teratogenicity of medications and a
revalence of hypertension lower than that in men through
iddle age (9,13).
Eleven percent of premenopausal women from the
resent study reported a history of hormone therapy use.
enstrual irregularities in these women could be one
xplanation for their prescribed hormone therapy. As pre-
iously reported (66), a substantial proportion of the pre-
enopausal WISE study women have reproductive hor-
one profiles and symptoms consistent with hypothalamic
ypoestrogenemia, often with associated anovulatory cycles
nd amenorrhea.
Novel risk factors, including central estrogen deficiency
nd anovulatory status (66), should therefore be investigated
s both a mechanism of CAD in premenopausal women and
pathophysiologic participant in the relatively more adverse
utcomes experienced in premenopausal women than in
ge-matched men (34). Indeed, disruption of ovulatory
ycling characterized by hypoestrogenemia of hypothalamic
rigin was associated with angiographic CAD among the
remenopausal WISE study women in a prior study (66).
entral estrogen deficiency in premenopausal women could
otentially impact SBP and PP through a variety of mech-
nisms. Recent epidemiologic and experimental evidence
ndicate that estrogen deficiency may cause increases in SBP
nd elevated PP through impacting endothelial vascularunction and/or systemic arterial compliance (13,16,67,68).
his hypothesis warrants further investigation.
tudy limitations. The current study results are limited by
ur cross-sectional design which precludes inference regard-
ng causality between hypertension, additional coronary risk
actors, and angiographic CAD. Also, although angio-
raphically confirmed CAD represents an advantage over
oninvasive cardiovascular markers, this study is limited in
ts capacity to link these coronary risk factor analyses to
dverse coronary events, such as coronary mortality. Use of
clinically referred coronary angiography population also
educes our ability to detect relationships between risk
actors and angiographic CAD, owing to a selection bias
hereby participants with risk factors are preferentially
eferred for angiography. In addition, the subgroup analyses
re limited by our small sample size of premenopausal
omen with CAD, and the multivariable analyses may be
imited by mild collinearity between age and menopausal
tatus. Finally, the WISE study population of women,
elected because they were undergoing coronary angiogra-
hy for suspected myocardial ischemia, may not be repre-
entative of the relationships between menopausal status,
oronary risk factors, and CAD in the general population of
omen. However, the WISE study cohort includes women
ho exhibit a broad range of angiographically documented
AD. This study design provides a unique opportunity to
valuate associations among blood pressure, other tradi-
ional cardiac risk factors, and angiographic CAD in pre-
enopausal and postmenopausal women.
onclusions. Among women with coronary risk factors
ndergoing coronary angiography for suspected myocardial
schemia, 20% of premenopausal women had angiographic
AD versus 31% of postmenopausal women. Blood pres-
ure was differentially related to CAD according to meno-
ausal status, with high SBP and PP constituting a higher
isk in premenopausal versus postmenopausal women. This
ncreased risk was not attributable to age alone. These
esults suggest that identification of hypertension in pre-
enopausal women should dictate additional CAD risk
ssessment and risk factor management. Further research
imed at better understanding blood pressure, CAD risk,
nd therapeutics within the context of prospective measures
f endogenous hormones is needed if we are to optimize
AD outcomes in premenopausal women.
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